

ASX Announcement | 28 February 2024
Visioneering Technologies (ASX:VTI)

Visioneering Technologies, Inc. Announces Board Changes

Visioneering Technologies, Inc. (ASX: VTI) ('Visioneering', 'VTI' or 'the Company'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, today announced the retirement of David J. Mazzo, Ph.D. from its Board of Directors after four years of service as Chair. Dr. Mazzo's retirement will become effective on 29 February 2024, coincident with the filing of the Company's Appendix 4E and accompanying audited financial statements as of and for the year ended 31 December 2023. Dr. Mazzo cited the need to focus on other commitments as the principal reason for his departure.

Dr. Mazzo joined VTI's Board of Directors as Chair in March 2020. He helped guide the Company through the challenges of the COVID-19 pandemic, led the initiative to begin what is now the PROTECT Clinical Trial, a critically important step in VTI's evolution, and played an integral role in attracting Dr. Juan Carlos Aragón ("JC") to the Company as CEO.

Dr. Mazzo stated: "I have thoroughly enjoyed my tenure as Chair of VTI and remain a stalwart supporter of the Company and its products, especially based on the positive PROTECT Clinical Trial data that the Company has communicated. I am particularly optimistic about VTI's future under JC's leadership and look forward to the company achieving great success for patients and shareholders in the future."

VTI CEO and Executive Director Dr. Juan Carlos Aragón commented: "I am grateful for David's service to the Company. I joined VTI just a few months ago and worked closely with David during my transition into VTI. He was very gracious with his time and extremely helpful to me as I set and refined my strategic plan for the Company. While I am saddened by his departure, I understand and respect his decision. I wish him continued success."

The Board has elected Kathleen Miller as Interim Chair while the Company undertakes a process to appoint a new Chair. Ms. Miller joined VTI's Board of Directors in December 2022 as an independent non-executive director and chair of the Audit & Risk Committee. Ms. Miller is an experienced public company board member and Audit Committee Chair with over 30 years of leading and advising boards of public and high-growth companies on finance, accounting, compensation, mergers & acquisitions, governance, strategy, and operations.

Ends

This release was authorised by the CEO, Dr. Juan Carlos Aragón.

For more information, please contact:

Company	Investor and media relations
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres H^CK Tel: +61 423 139 163 Email: haley@hck.digital

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day™ Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtivision.com or call +1 844-884-5367, ext. 104.

Foreign ownership restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans, and expectations and information currently available to management.

All statements that address operating performance, events, or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the ongoing impact of COVID-19 on the trading conditions impacting VTI, the financial markets, and the health services worldwide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments, or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX89